Pharmaceutical

AbbVie achieves win for migraine prevention drug Aquipta in Europe

The decision brings the first daily oral migraine prophylactic to Europe, with plans to rollout the treatment as soon as possible.

Aug 18, 2023 - 20:00
AbbVie achieves win for migraine prevention drug Aquipta in Europe
The decision brings the first daily oral migraine prophylactic to Europe, with plans to rollout the treatment as soon as possible.
Read the original article

Tags:

Previous Article

STAT+: With an age cutoff for a new gene therapy, families and doctors scramble ...

Next Article

Boehringer Ingelheim advances weight loss drug to Phase III trials

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug

STAT+: Viking Therapeutics releases early but promising...

Mar 28, 2023

AbbVie reports 9.7% fall in global net revenues for Q1 2023

AbbVie reports 9.7% fall in global net revenues for Q1 ...

Apr 28, 2023

STAT+: Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle

STAT+: Alarmed by popularity of Ozempic and Wegovy, ins...

Aug 3, 2023